Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease

The 1-year and median overall survivals (mOS) of advanced gastroesophageal adenocarcinomas (GEA) are ~50% and <12 months. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled wi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Catenacci, Daniel V.T., Moya, Stephanie, Lomnicki, Samantha, Chase, Leah M., Peterson, Bryan F., Reizine, Natalie, Alpert, Lindsay, Setia, Namrata, Xiao, Shu-Yuan, Hart, John, Siddiqui, Uzma D., Hogarth, D. Kyle, Eng, Oliver S., Turaga, Kiran, Roggin, Kevin, Posner, Mitchell C., Chang, Paul, Narula, Sunil, Rampurwala, Murtuza, Ji, Yuan, Karrison, Theodore, Liao, Chih-Yi, Polite, Blase N., Kindler, Hedy L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7858231/
https://ncbi.nlm.nih.gov/pubmed/33234578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-1408
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi